Advenchen Laboratories Nanjing

Advenchen Laboratories is a research-driven biotechnology company focused on the discovery and development of small molecule therapeutics for oncology. Founded by Dr. Guan-Shan Chen, the company is best known for discovering Apatinib (Rivoceranib), a potent VEGFR-2 inhibitor that is commercialized in China by Jiangsu Hengrui Pharmaceuticals. Advenchen maintains a robust pipeline of multi-kinase inhibitors targeting VEGFR, FGFR, and PDGFR pathways. The company operates through its headquarters in the United States and its primary research facility, Nanjing Advenchen Laboratories, in China. Its business model emphasizes early-stage discovery and licensing partnerships for late-stage clinical development and commercialization.